default author photo

Fenglin Li

Zhejiang University - Department of Hematology

China

Key Laboratory of Hematopoietic Malignancies

Zhejiang

China

SCHOLARLY PAPERS

3

DOWNLOADS

274

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

MAP4K1 Functions as a Tumor Promotor and Drug Mediator for AML via Modulation of DNA Damage/Repair System and MAPK Pathway

Number of pages: 28 Posted: 26 Jan 2021
Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University - Department of Hematology, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Fudan University - Department of Neurology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University - Department of Hematology and Zhejiang University - Department of Hematology
Downloads 135

Abstract:

Loading...

Acute myeloid leukemia, MAP4K1, Homoharringtonine resistance, Prognosis, DNA damage, MAPK

2.

A Novel Role for Malate Dehydrogenase 1 in Acute Myeloid Leukemia Progression

Number of pages: 165 Posted: 26 May 2019
Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, City of Hope - Beckman Research Institute, Zhejiang University - Department of Hematology and Zhejiang University - Department of Hematology
Downloads 93

Abstract:

Loading...

malate dehydrogenase 1; anti-oncogene; acute myeloid leukemia

3.

High PARP-1 Expression Predicts Poor Survival in Acute Myeloid Leukemia and PARP-1 Inhibitor and Saha-Bendamustine Hybrid Inhibitor Combination Treatment Synergistically Enhances Anti-Tumor Effects

, EBioMedicine, Volume 38, December 2018, Pages 47-56, https://doi.org/10.1016/j.ebiom.2018.11.025
Number of pages: 47 Posted: 24 Sep 2018
Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Hangzhou First People’s Hospital, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - College of Pharmaceutical Sciences and Zhejiang University - Department of Hematology
Downloads 46

Abstract:

Loading...

PARP-1, Acute myeloid leukemia, PARP inhibitor, SAHAbendamustine hybrid